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Background/Purpose: The study was conducted to determine the effect of preinjection ocular decom-
pression by a cotton swab soaked in local anesthetic on the immediate postinjection rise in intraocular
pressure (IOP) after intravitreal bevacizumab (IVB).
Methods: A nonrandomized, quasi-experimental interventional study was conducted at Al-Shifa Trust
Eye Hospital, Pakistan, from August 1, 2013 to July 31, 2014. One hundred (n ¼ 100) patients receiving
0.05-mL IVB injection for the ﬁrst time were assigned to two preinjection anesthetic methods: one with
ocular decompression using a sterile cotton swab soaked in proparacaine 0.5%, and the other without
ocular decompression using proparacaine 0.5% eyedrops. The IOP was recorded in the eye receiving IVB
at three time intervals: Time 1 (preinjection), Time 2 (immediately after injection), and Time 3 (30 mi-
nutes after injection).
Results: There was a signiﬁcant difference in the mean IOP change (between Time 1 and Time 2) for the
group injected with ocular decompression [M ¼ 1.00, standard deviation (SD) ¼ 1.47] and the group
injected without ocular decompression (M ¼ 5.00, SD ¼ 2.38; t (68) ¼ 9.761, p < 0.001). There was also a
signiﬁcant difference in the mean IOP change (between Time 1 and Time 3) for the group injected with
ocular decompression (M ¼ 0.428, SD ¼ 1.58) and the group injected without ocular decompression
(M ¼ 4.318, SD ¼ 3.34; t (58) ¼ 7.111, p < 0.001).
Conclusion: Patients receiving IVB injections with ocular-decompression soaking in proparacaine 0.5%
experience signiﬁcantly lower postinjection IOP spike, and that too for a considerably shorter duration as
compared to those receiving IVB without ocular decompression.
Copyright © 2016, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The use of repeated intravitreal injections has become a familiar
treatment modality for a wide range of retinal diseases. Current
practices include the use of intravitreal bevacizumab (IVB), dexa-
methasone, and triamcinolone for problems ranging from diabetic
macular edema to vitreous hemorrhage.1 The patients may receivere is no conﬂict of interests
alone are responsible for the
lare that no ﬁnancial support
a, Al-Shifa Trust Eye Hospital,
. Mansoor).
iety of Taiwan. Published by Elseviintravitreal injections at regular intervals, and the periodicity may
be as frequent as every 2 weeks.2
Injecting an additional volume of an intravitreal agent may
result in an acute short-term rise of intraocular pressure (IOP),
which can ultimately occlude the central retinal artery momen-
tarily. This phenomenon can be attributed to the noncompliant
nature of the spherical globe, and can pose a serious threat to the
vision.3 This can be explained as elevated IOP impairs the retinal
and optic-nerve-head blood ﬂow, it results in mechanical damage
of the optic-nerve axons.4
A review of international literature shows that transient, yet
extreme, elevation of IOP, after IVB injection, at times, takes about
30 minutes to return to baseline levels.5 Contrary to this, there areer Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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2 hours after IVB injection. Hollands et al6 reported the use of
topical antiglaucoma medication for a period of 1 week to control
the IOP after an IVB injection.
Patients who have a prior history of glaucoma have a propensity
to sustain elevated IOP after IVB injections for longer durations. The
elevated IOP in these patients usually takes longer to return to
baseline.7 It is therefore imaginable that these elevated IOP spikes
after IVB injections, repeated almost every month for years as long
as the treatment continues, may consequently damage the optic-
nerve axons permanently in normotensive patients in general
and in patients with preexisting glaucoma in particular.8,9
Keeping in view the grave consequences of sustained IOP
elevation after IVB injections, efforts should be done to minimize
the rise in IOP after IVB injections. Moreover, the international
literature proposes lowering of preinjection IOP by ocular decom-
pression and/or with medication.8e10
In our attempt to minimize the postinjection spike in IOP after
IVB injection, this study was conducted to determine the rise in IOP
after 0.05 mL of intravitreal anti-vascular endothelial growth factor
(VEGF) (IVB) injection using two preinjection anesthetic methods.
2. Methods
A nonrandomized, quasi-experimental interventional study was
conducted at the Department of Retina of Al-Shifa Trust Eye Hos-
pital, Rawalpindi, Pakistan, fromAugust 1, 2013 to July 31, 2014. The
study was approved by the Institutional Ethical and Research
Committee. A written informed consent was taken from all the
participants of the study.
A total of 100 (n ¼ 100) patients were included in the current
study. Only those patients who were receiving intravitreal anti-
VEGF (IVB) injection for the ﬁrst time were included in the cur-
rent study. All those patients who had already received any kind of
intravitreal injection or had previously raised IOP due to any cause
were excluded from the study.
In our attempt to minimize the postinjection spike in IOP after
IVB injection, this study was conducted to determine the rise in IOP
after 0.05 mL of IVB injection using two preinjection anesthetic
methods: one with ocular decompression using a sterile cotton
swab soaked in proparacaine 0.5%, pressed for 30 seconds, at
3.5 mm inferotemporally from the limbus measured by a sterile
caliper (injection site) before IVB injection; and the other without
ocular decompression, using proparacaine 0.5% eyedrops, one drop
repeated three times at 1-minute intervals.
The IOP was recorded by Goldmann applanation tonometer in a
sitting position using slit-lamp biomicroscopy, in the eye receiving
IVB at three time intervals: Time 1 (preinjection and before ocular
decompression/ocular manipulation), Time 2 (immediately after
injection), and Time 3 (30 minutes after injection). The ocular
decompression and IVB injection were administered to all the
studied patients by the same treating ophthalmologist (Naveed A.
Qureshi). Similarly, the IOP measurements at Time 1, Time 2, and
Time 3 were recorded by the same ophthalmologist (H.M.). None of
the patients received pressure-lowering drugs or underwent
anterior-chamber paracentesis before or after the IVB injection.
After the IOP recording at Time 1, the lids and lashes were
cleaned by 10% povidone-iodine swab. A standard sterile lid spec-
ulum was used in both anesthetic techniques, which was removed
before the ﬁrst postinjection IOP recording (Time 2), and 5% liquid
povidone-iodine solution was applied on the ocular surface and
conjunctival fornices for 60 seconds. The ocular decompression
using a cotton swab soaked in proparacaine 0.5% at the injection
site in the inferotemporal quadrant was gauged by applying mod-
erate pressure to cause visible circular indentation of the globe. Asthe cotton swab was removed, an additional drop of 5% liquid
povidone-iodine solution was applied at the injection site. A sterile
30-gauge needle attached to a 1-mL syringe was used for the IVB
injection at the designated injection site, which was followed by a
cotton swab covering the injection site momentarily (without
application of pressure) to avoid egress of vitreous as the needle
was withdrawn from the cavity. The IOP was then recorded by
Goldmann applanation tonometer in a sitting position using slit-
lamp biomicroscopy in the eye receiving IVB at Time 2 and Time 3.
Statistical analysis was performed by using SPSS version 17.0
(SPSS Inc., Chicago, IL, USA). A value of p < 0.05 was taken to
indicate statistical signiﬁcance.
A one-way repeatedmeasures analysis of variance (ANOVA) was
conducted to evaluate the mean IOP change following intravitreal
anti-VEGF injection (IVB) with ocular decompression at Time 1,
Time 2, and Time 3. A one-way repeated measures ANOVAwas also
conducted to evaluate the mean IOP change following intravitreal
anti-VEGF (IVB) injection without ocular decompression at Time 1,
Time 2, and Time 3.
An independent-sample t test was conducted to compare the
mean IOP change before the injection (Time 1) and immediately
after the injection (Time 2) between the two groups (i.e., with
ocular decompression and without ocular decompression). An
independent-sample t test was also conducted to compare the
mean IOP change before the injection (Time 1) and 30minutes after
the injection (Time 3) between the two groups (i.e., with ocular
decompression and without ocular decompression).
3. Results
A total of one hundred (n ¼ 100) patients were included in the
current study with 60 (n¼ 60) males (60%) and 40 (n¼ 40) females
(40%). The right eye (OD) received intravitreal anti-VEGF (IVB) in-
jection in 55% (n ¼ 55) of the cases, whereas the left eye (OS)
received the same injection in 45% (n ¼ 45) of the cases. Fifty-six
patients (n ¼ 56) received intravitreal anti-VEGF (IVB) injection
following ocular decompression, and 44 (n ¼ 44) patients received
intravitreal anti-VEGF (IVB) injection without ocular decompres-
sion, accounting for 56% and 44%, respectively, of the study
population.
The one-way repeated measures ANOVA conducted to evaluate
the mean IOP change following intravitreal anti-VEGF injection
(IVB) with ocular decompression at Time 1, Time 2, and Time 3
showed signiﬁcant effect for time, Wilks's lambda ¼ 0.682, F (2,
52)¼ 11.197, p < 0.005, and multivariate partial h2¼ 0.318. The post
hoc Bonferroni test revealed that there was a signiﬁcant difference
between the mean IOP before the injection and the mean IOP
immediately after the injection, with a mean difference ¼ 1.00 and
p < 0.001. There was also a signiﬁcant difference between the mean
IOP immediately after injection and 30minutes after injection, with
a mean difference ¼ 0.571 and p ¼ 0.043. However, no signiﬁcant
differencewas observed between themean IOP before the injection
and the mean IOP 30 minutes after the injection, with a mean
difference ¼ 0.429 and p ¼ 0.143 (Table 1).
The one-way repeated measures ANOVA conducted to evaluate
the mean IOP change following intravitreal anti-VEGF (IVB) injec-
tion without ocular decompression at Time 1, Time 2, and Time 3
showed a signiﬁcant effect for time, Wilks's lambda ¼ 0.176, F (2,
42) ¼ 72.504, p < 0.005, and multivariate partial h2 ¼ 0.824. The
post hoc Bonferroni test revealed that there was a signiﬁcant dif-
ference between the mean IOP before the injection and the mean
IOP immediately after the injection, with a mean difference¼ 5.024
and p < 0.001. There was also a signiﬁcant difference between the
mean IOP before the injection and the mean IOP 30 minutes after
the injection, with a mean difference ¼ 4.238 and p < 0.001.
Table 1
Comparison of means within the groups.
Group according to intervention technique N Mean ± SD CI df F p
Lower bound Upper bound df 1 df 2
With ocular decompression IOP before injection 56 14.611 ± 3.531 14.018 15.910 2 54 11.197 <0.001
IOP immediately after injection 15.532 ± 3.903 14.919 17.010
IOP after 30 minutes of injection 14.929 ± 3.836 14.365 16.420
Without ocular decompression IOP before injection 44 12.476 ± 2.830 11.642 13.406 2 42 72.504 <0.001
IOP immediately after injection 17.497 ± 3.086 16.586 18.509
IOP after 30 minutes of injection 16.523 ± 4.487 15.363 18.160
CI ¼ conﬁdence interval; df ¼ degree of freedom; IOP ¼ intraocular pressure; SD ¼ standard deviation.
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IOP immediately after the injection and after 30 minutes of injec-
tion, with a mean difference of 0.786 and p ¼ 0.352 (Table 1).
The independent-sample t test conducted to compare the mean
IOP change before the injection and immediately after the injection
between the two groups (i.e., with ocular decompression and
without ocular decompression) revealed a signiﬁcant difference in
the mean IOP change for the group injected with ocular decom-
pression [M ¼ 1.00, standard deviation (SD) ¼ 1.47] and the group
injected without ocular decompression (M ¼ 5.00, SD ¼ 2.38; t
(68) ¼ 9.761, p < 0.001, two tailed). The magnitude of the differ-
ences in the means of these two groups was 4.00 (mean
difference ¼ 4.00, 95% conﬁdence interval 3.182e4.817) (Table 2).
The independent-sample t test conducted to compare the mean
IOP change before the injection and 30 minutes after the injection
between the two groups (i.e., with ocular decompression and
without ocular decompression) showed a signiﬁcant difference in
the mean IOP change for the group injected with ocular decom-
pression (M ¼ 0.428, SD ¼ 1.58) and the group injected without
ocular decompression [M ¼ 4.318, SD ¼ 3.34; t (58) ¼ 7.111,
p < 0.001, two tailed]. The magnitude of the differences in the
means of these two groups was 3.89 (mean difference ¼ 3.89, 95%
conﬁdence interval 2.794e4.984; Table 2).4. Discussion
It has been well expressed in the international literature that
intravitreal anti-VEGF agents, with introduction of additional ﬂuid
in the vitreous cavity, can lead to a momentary elevation in the
IOP.5 This phenomenon has also been seen after intravitreal anti-
biotic and steroid injections. Moreover, the transient elevation of
IOP normalizes within 30minutes in majority of the eyes.6 Contrary
to this claim, long-term sustained elevation of IOP has also been
reported in some eyes receiving anti-VEGF therapy.11,12
The long-term effects of repeated IOP elevation in patients
receiving several intravitreal anti-VEGF agents are not known.
Whether such transient elevation in IOP warrants the need for
antiglaucoma therapy is still debatable. Eyes with preexisting
glaucoma aremore susceptible to damage. Also, glaucomatous eyes
take longer to return to preinjection pressure levels.7 In our attempt
to minimize the postinjection spike in IOP after IVB injection, the
current study was conducted to determine the elevation in IOPTable 2
Comparison of mean differences between the two groups.
Group according to inter
IOP change between, before, & immediately after injection With ocular decompress
Without ocular decompr
IOP change between, before, & 30 minutes after injection With ocular decompress
Without ocular decompr
df ¼ degree of freedom; IOP ¼ intraocular pressure; SD ¼ standard deviation.after 0.05 mL of IVB (anti-VEGF) injection using two preinjection
anesthetic methods.
The physiological response of the eye to elevated IOP leads to
increased aqueous-humor drainage through the trabecular
meshwork and uveoscleral routes.13 Primarily, aqueous humor
drains through the trabecular meshwork across a pressure-
dependent gradient into the canal of Schlemm, which commu-
nicates directly with the episcleral veins. Goldmann14 analyzed
the aqueous-humor ﬂow and stated that, as the globe is indented,
the volume of ﬂuid exiting the eye exceeds the volume of ﬂuid
ﬂowing in by aqueous-humor production. He also opined that a
reduction in the intraocular volume is manifested as lowered
IOP, thus permitting the additional ﬂuid to be injected in the form
of intravitreal injections.14 This phenomenon lowers the risk of
experiencing abnormally high IOP after intravitreal anti-VEGF
injections.
Kim and Jee10 used the tunneled scleral technique to study the
effect of Honan intraocular pressure reducer (HIPR) on IOP rise after
an intravitreal injection. They showed that the use of HIPR resulted
in signiﬁcantly lowering the preinjection, immediate postinjection,
as well as 10-minute postinjection IOP levels as compared to the
non-HIPR group. Since the use of HIPR was cumbersome, other
methods of decompressing the eye had to be considered.10
Gregori et al5 showed that preinjection decompression of the
eye with cotton swabs using 4% liquid lidocaine preparation during
an anesthetic preparation led to a signiﬁcantly lowered post-
injection IOP spike. The current study used a different anesthetic
agent, and showed that ocular decompression using cotton swabs
soaked in proparacaine 0.5% also resulted in signiﬁcantly lowered
postinjection IOP spike as compared to topical anesthesia without
ocular decompression. Davis et al15 showed that topical propar-
acaine 0.5% compared to 4% lidocaine preparation is inexpensive
and provides a very effective anesthesia during ofﬁce-based intra-
vitreal injections. It also has minimum side effects and is easily
administered.16 Kozak et al17 compared different anesthetic
methods used for intravitreal injections, and concluded that topical
proparacaine eyedrops had the lowest average combined pain
score. However, Andrade and Carvalho18 recommended that topical
proparacaine may be coupled with subconjunctival lidocaine to
avoid pain and eye movements during intravitreal injections.
The current study shows that irrespective of whether ocular
decompression was done or not, a signiﬁcant raise in IOP was seen
immediately after intravitreal anti-VEGF (IVB) injection. Moreover,vention technique N Mean SD Mean difference t df p
ion 56 1.00 1.47 4.00 9.761 68 <0.001
ession 44 5.000 2.38
ion 56 0.429 1.58 3.89 7.111 58 <0.001
ession 44 4.318 3.34
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vitreal anti-VEGF (IVB) agent without ocular decompression even
30 minutes after the injection. This was not seen in patients
receiving intravitreal anti-VEGF (IVB) agents with ocular decom-
pression. Therefore, in patients who receive intravitreal injections
with ocular decompression, IOP returns to near normal levels
sooner as compared to those who receive intravitreal injections
without ocular decompressing, thus posing a serious risk to
adversely affect the eye due to raised IOP.
The current study also shows that, although the mean change in
IOP before and immediately after the injection was statistically
signiﬁcant (p  0.001) in both groups, the mean change in IOP in
the group without ocular decompression (5.00 ± 2.38) was more
compared to the mean change in IOP in the group with ocular
decompression (1.00 ± 1.47). Likewise, the mean change in IOP
before the injection and 30 minutes after the injection between the
two groups (i.e., with ocular decompression and without ocular
decompression) was also statistically signiﬁcant (p  0.001). Also,
the mean change in IOP in the group without ocular decompression
(4.32 ± 3.34) was more compared to the mean change in IOP in the
group with ocular decompression (0.43 ± 1.58) even 30 minutes
after the injection.
Furthermore, the current study lays emphasis the fact that pa-
tients receiving intravitreal anti-VEGF (IVB) injections without
ocular decompression experience signiﬁcantly higher postinjection
IOP, and for a considerably longer duration compared to those
receiving intravitreal injections with ocular decompression. It is
therefore advisable to use ocular decompression during intravitreal
injections to avert grave visual consequences.
The critics of the proposed method of reducing the post-
injection (IVB) IOP spike in the current study may raise the
question of raised IOP during cotton-swab application. In fact,
Gregori et al5 came across one patient, in which the IOP rose to
68 mmHg during preinjection anesthetic preparation using cotton
swabs. In their study, despite experiencing short-term preinjection
raised IOP, anesthetic preparation using a cotton swab resulted in
shorter as well as signiﬁcantly lowered IOP spike postinjection
(IVB).5 We did not come across any patient who showed a bizarre
raise in IOP during anesthetic preparation using ocular
decompression.
Another advantage of using the proposed technique by the au-
thors as compared to the HIPR is that cotton swabs soaked in local
anesthetic provide anesthesia and ocular decompression at the
same time, making it a time-efﬁcient tool to reduce alarming
postinjection (IVB) spike.
Kim et al7 stated that a smaller needle size and a larger volume
of intravitreal injection have a role to play in sustained high IOP
postinjection. They were of the opinion that smaller needle bore
size reduces the pain and vitreous reﬂux simultaneously, and
hence, used in clinical practice frequently.7 They also showed that
30- or 32-gauge needles used for injecting 0.05 mL of intravitreal
injections caused higher postinjection IOP compared to a 27-gauge
needle injection (0.1 mL). In the current study, the authors used30-gauge needle for 0.05 mL of intravitreal anti-VEGF (IVB) agent,
further compelling the need for ocular decompression.
In conclusion, the current study shows that ocular decompres-
sion with cotton swabs soaked in proparacaine 0.5% produces a
signiﬁcantly lowered postinjection (IVB) spike compared to other
topical anesthesia without ocular decompression. As patients
around the world continue to receive frequent intravitreal in-
jections, efforts should be done to minimize the rise in IOP after
intravitreal injections to avoid severe visual morbidities.References
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